TRDA Insider Trading

Insider Ownership Percentage: 7.22%
Insider Buying (Last 12 Months): $772,170.69
Insider Selling (Last 12 Months): $718,377.67

Entrada Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Entrada Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Entrada Therapeutics Share Price & Price History

Current Price: $14.15
Price Change: Price Increase of +0.15 (1.07%)
As of 10/6/2022 04:59 PM ET

This chart shows the closing price history over time for TRDA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Entrada Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/28/2022Dipal DoshiCEOSell3,085$15.23$46,984.55204,835View SEC Filing Icon  
9/28/2022Nerissa KreherInsiderSell3,122$15.25$47,610.5020,716View SEC Filing Icon  
9/26/2022Dipal DoshiCEOSell3,083$15.32$47,231.56212,339View SEC Filing Icon  
9/26/2022Nathan J DowdenCOOSell1,544$15.45$23,854.8062,811View SEC Filing Icon  
9/26/2022Nerissa KreherInsiderSell3,068$15.33$47,032.4420,716View SEC Filing Icon  
9/23/2022Dipal DoshiCEOSell1,023$15.07$15,416.61215,422View SEC Filing Icon  
9/23/2022Nathan J DowdenCOOSell1,018$15.07$15,341.2664,355View SEC Filing Icon  
9/23/2022Nerissa KreherInsiderSell939$15.09$14,169.5120,716View SEC Filing Icon  
9/21/2022Dipal DoshiCEOSell3,402$15.12$51,438.24216,445View SEC Filing Icon  
9/21/2022Nathan J DowdenCOOSell3,275$15.13$49,550.7565,373View SEC Filing Icon  
9/21/2022Nerissa KreherInsiderSell3,341$15.08$50,382.2820,716View SEC Filing Icon  
9/15/2022Dipal DoshiCEOSell200$15.04$3,008.00219,847View SEC Filing Icon  
9/15/2022Nathan J DowdenCOOSell100$15.01$1,501.0068,648View SEC Filing Icon  
9/15/2022Nerissa KreherInsiderSell106$15.01$1,591.0620,716View SEC Filing Icon  
9/9/2022Nerissa KreherInsiderSell800$15.07$12,056.0020,716View SEC Filing Icon  
9/8/2022Dipal DoshiCEOSell1,100$15.16$16,676.00220,735View SEC Filing Icon  
9/8/2022Nathan J DowdenCOOSell912$15.15$13,816.8069,613View SEC Filing Icon  
8/31/2022Dipal DoshiCEOSell171$12.00$2,052.00206,710View SEC Filing Icon  
8/29/2022Dipal DoshiCEOSell1,639$12.88$21,110.32207,071View SEC Filing Icon  
8/25/2022Kory James WentworthCFOSell1,551$14.18$21,993.1810,986View SEC Filing Icon  
8/23/2022Kory James WentworthCFOSell2,909$13.09$38,078.8114,538View SEC Filing Icon  
8/18/2022Kory James WentworthCFOSell200$13.00$2,600.0020,221View SEC Filing Icon  
8/16/2022Kory James WentworthCFOSell200$13.00$2,600.0020,441View SEC Filing Icon  
7/27/2022Dipal DoshiCEOSell2,000$12.00$24,000.00208,710View SEC Filing Icon  
6/27/2022Dipal DoshiCEOSell4,000$12.00$48,000.00210,710View SEC Filing Icon  
6/27/2022Nathan J DowdenCOOSell7,714$13.00$100,282.0064,893View SEC Filing Icon  
6/6/2022Bros. Advisors Lp BakerMajor ShareholderBuy38,304$6.41$245,528.644,501,658View SEC Filing Icon  
6/2/2022Bros. Advisors Lp BakerMajor ShareholderBuy2,643$5.82$15,382.264,467,393View SEC Filing Icon  
5/23/2022Bros. Advisors Lp BakerMajor ShareholderBuy7,837$5.99$46,943.634,443,719View SEC Filing Icon  
5/20/2022Bros. Advisors Lp BakerMajor ShareholderBuy16,849$5.84$98,398.164,436,709View SEC Filing Icon  
5/18/2022Bros. Advisors Lp BakerMajor ShareholderBuy34,433$6.00$206,598.004,421,689View SEC Filing Icon  
5/16/2022Bros. Advisors Lp BakerMajor ShareholderBuy19,000$5.83$110,770.004,374,493View SEC Filing Icon  
1/12/2022John F. CrowleyDirectorBuy5,000$9.71$48,550.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Entrada Therapeutics (NASDAQ:TRDA)

79.02% of Entrada Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TRDA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Entrada Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/16/2022Price T Rowe Associates Inc. MD2,437,498$29.69M0.0%-2.3%7.770%Search for SEC Filing on Google Icon
8/15/2022State Street Corp30,194$0.37M0.0%-80.0%0.096%Search for SEC Filing on Google Icon
8/15/2022Citadel Advisors LLC12,947$0.16M0.0%-79.9%0.041%Search for SEC Filing on Google Icon
8/15/2022Laurion Capital Management LP129,066$1.57M0.0%N/A0.411%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC76,498$0.93M0.0%N/A0.244%Search for SEC Filing on Google Icon
8/12/2022Northern Trust Corp16,328$0.20M0.0%-81.9%0.052%Search for SEC Filing on Google Icon
8/12/2022FMR LLC944,908$11.51M0.0%+7.8%3.012%Search for SEC Filing on Google Icon
6/7/2022Bank of America Corp DE20,871$0.20M0.0%-8.6%0.067%Search for SEC Filing on Google Icon
5/27/2022Walleye Capital LLC44,652$0.42M0.0%N/A0.142%Search for SEC Filing on Google Icon
5/17/2022Walleye Capital LLC44,652$0.42M0.0%N/A0.142%Search for SEC Filing on Google Icon
5/16/2022Wellington Management Group LLP2,543,102$23.82M0.0%-18.3%8.108%Search for SEC Filing on Google Icon
5/16/2022State Street Corp151,194$1.42M0.0%+86.4%0.482%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC11,800$0.11M0.0%-13.1%0.038%Search for SEC Filing on Google Icon
5/13/2022Nan Fung Group Holdings Ltd173,582$1.63M0.8%N/A0.553%Search for SEC Filing on Google Icon
5/13/2022Northern Trust Corp90,258$0.85M0.0%+13.6%0.288%Search for SEC Filing on Google Icon
5/13/2022Charles Schwab Investment Management Inc.68,704$0.65M0.0%+7.3%0.219%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.430,404$4.04M0.0%+1.3%1.372%Search for SEC Filing on Google Icon
5/11/2022Bank of New York Mellon Corp21,933$0.21M0.0%+60.6%0.070%Search for SEC Filing on Google Icon
5/5/2022New York State Common Retirement Fund4,880$46K0.0%N/A0.016%Search for SEC Filing on Google Icon
2/18/2022TCG Crossover Management LLC663,694$11.36M5.3%N/A2.126%Search for SEC Filing on Google Icon
2/14/2022Redmile Group LLC1,954,420$33.46M0.8%N/A6.262%Search for SEC Filing on Google Icon
2/14/202272 Investment Holdings LLC509,024$8.71M7.7%N/A1.631%Search for SEC Filing on Google Icon
2/14/2022Suvretta Capital Management LLC106,000$1.82M0.0%N/A0.340%Search for SEC Filing on Google Icon
2/14/2022Ghisallo Capital Management LLC15,000$0.26M0.0%N/A0.048%Search for SEC Filing on Google Icon
2/14/2022Goldman Sachs Group Inc.7,626,182$130.56M0.0%N/A24.433%Search for SEC Filing on Google Icon
2/11/2022MPM Asset Management LLC4,425,784$75.77M16.4%N/A14.179%Search for SEC Filing on Google Icon
2/10/2022TD Asset Management Inc.57,675$0.99M0.0%N/A0.185%Search for SEC Filing on Google Icon
2/8/2022Northern Trust Corp79,483$1.36M0.0%N/A0.255%Search for SEC Filing on Google Icon
2/3/20225AM Venture Management LLC4,408,379$75.47M14.2%N/A14.124%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Entrada Therapeutics logo
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More on Entrada Therapeutics

Today's Range

Now: $14.15
Low: $13.88
High: $14.72

50 Day Range

MA: $13.38
Low: $10.76
High: $16.00

52 Week Range

Now: $14.15
Low: $5.12
High: $36.85


1,076 shs

Average Volume

88,320 shs

Market Capitalization

$443.89 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Entrada Therapeutics?

Entrada Therapeutics' top insider shareholders include:
  1. Bros Advisors Lp Baker (Major Shareholder)
  2. Dipal Doshi (CEO)
  3. Nathan J Dowden (COO)
  4. Nerissa Kreher (Insider)
  5. Kory James Wentworth (CFO)
  6. John F Crowley (Director)
Learn More about top insider investors at Entrada Therapeutics.